Treatment of staphylococcal skin infections: a comparison of cephalexin and dicloxacillin.
Cephalexin, given twice daily, and dicloxacillin, given four times daily, were compared in a randomly controlled study for the treatment of staphylococcal skin and skin structure infections. Among 70 evaluable patients, 57 had staphylococcal bullous impetigo. The remaining 13 patients had bullous impetigo with streptococcal or mixed streptococcal-staphylococcal cultures (6 patients), abscess (4 patients), or cellulitis with pyoderma (3 patients). Staphylococci were recovered from lesions of 64 of the 70 evaluable patients; all strains were sensitive to both cephalexin and dicloxacillin, but only 2 of the 64 strains were susceptible to penicillin G. Cephalexin and dicloxacillin proved equally effective. Treatment failures were uncommon (1 patient in each group), and recurrences (3 patients in each group) were limited to patients with bullous impetigo. In general, patients with staphylococcal bullous impetigo responded promptly, with clearing of lesions evident within the first week, but delayed healing with persistence of staphylococci in lesions was more common in the group receiving dicloxacillin. Twice-daily dosing with oral antibiotics is obviously convenient and may enhance compliance. Twice-daily therapy with cephalexin for staphylococcal skin and skin structure infections can be recommended with confidence.
D000038:Abscess / Q000188:drug therapy; D000293:Adolescent; D002481:Cellulitis / Q000188:drug therapy; D002506:Cephalexin / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004009:Dicloxacillin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007169:Impetigo / Q000188:drug therapy; D007223:Infant; D008297:Male; D011711:Pyoderma / Q000188:drug therapy; D012874:Skin Diseases, Infectious / Q000188:drug therapy*; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013290:Streptococcal Infections / Q000188:drug therapy
D004009:Dicloxacillin; D002506:Cephalexin